Insmed (INSM) Q3 2026 Earnings Call: BRINSUPRI Drives Guidance Increase
Source Tradingkey
Key Takeaways
- BRINSUPRI generated $400.1 million in Q3 2026 revenue, up 29% sequentially. Insmed said the product surpassed $1 billion in revenue during its first four full quarters after launch.
- ARIKAYCE revenue reached $124.4 million, representing 9% year-over-year growth.
- Insmed raised 2026 BRINSUPRI revenue guidance to $1.35 billion-$1.40 billion and ARIKAYCE guidance to $460 million-$470 million.
- The company ended the quarter with approximately $1.1 billion in cash, cash equivalents and marketable securities. Management expects Insmed to achieve cash flow positivity in 2027.
- BRINSUPRI launched in Japan in October 2026. Management expects Japan to be the primary contributor to the product’s revenue outside the U.S.
- ARIKAYCE received FDA priority review for a potential expanded label in MAC lung disease, with a PDUFA target action date of January 28, 2027.
Core Financial Data
| Metric | Q3 2026 result | Change or context |
|---|---|---|
| BRINSUPRI revenue | $400.1 million | Up 29% sequentially |
| ARIKAYCE revenue | $124.4 million | Up 9% year over year |
| Cash, cash equivalents and marketable securities | Approximately $1.1 billion | Balance at quarter-end |
| Combined R&D and SG&A expenses | — | Up 40% year over year, reflecting BRINSUPRI launch investment and pipeline funding |
| Total company revenue year to date | More than $1 billion | Management disclosure |
| BRINSUPRI first four full quarters of revenue | More than $1 billion | Achieved blockbuster status, according to management |
Disclaimer: The content available on Mitrade Insights is provided for informational and marketing purposes only. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Recommended Articles
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookThe financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
The financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
Understand how the Strait of Hormuz shock moved markets, and what CFD traders watched next.
Ripple (XRP) and Stellar (XLM) are showing signs of recovery on Tuesday after rebounding slightly the previous day, following double-digit corrections last week.
WTI Price Forecast: Climbs above $86.00 as 100-day SMA breakout comes into playWest Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
West Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
Gold price (XAU/USD) holds steady near $4,335 after pulling back from an early-June top near $4,450 during the early Asian trading hours on Wednesday.
